Cargando…

Emerging Diagnostics and Therapeutics for Non-alcoholic Fatty Liver Disease

The obesity epidemic has pushed fatty liver disease, which consists of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, to the forefront of the 21st century. Disease identification can be done invasively with a liver biopsy or noninvasively through elastography and measurements of...

Descripción completa

Detalles Bibliográficos
Autores principales: Darbhanga, Jake, Krulikowski, Kiarra, Riskin, Suzanne I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676744/
https://www.ncbi.nlm.nih.gov/pubmed/38021846
http://dx.doi.org/10.7759/cureus.47821
_version_ 1785141350533955584
author Darbhanga, Jake
Krulikowski, Kiarra
Riskin, Suzanne I
author_facet Darbhanga, Jake
Krulikowski, Kiarra
Riskin, Suzanne I
author_sort Darbhanga, Jake
collection PubMed
description The obesity epidemic has pushed fatty liver disease, which consists of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, to the forefront of the 21st century. Disease identification can be done invasively with a liver biopsy or noninvasively through elastography and measurements of biomarkers, such as the alanine aminotransferase (ALT) and aspartate aminotransferase (AST) liver enzymes. Presently, there are no FDA-approved drugs on the market to treat the disease. Alternative medicinal treatments have been investigated, which include altering the intestinal microbiota and consuming anti-inflammatory, herbal-based, vitamin-based, and plant-based medications, in addition to following a healthy lifestyle. In this study, multiple databases were used to identify articles pertaining to fatty liver disease (FLD). Databases included Biomedical Reference Collection: Comprehensive, Cumulative Index of Nursing and Allied Health (CINAHL), Google Scholar, and PubMed. All articles gathered from the databases were peer-reviewed and less than 10 years old to ensure the credibility of the work and recent information regarding the disease. A total of 13 articles were used to gather information for this review. All articles were confirmed to be peer-reviewed by checking them with Ulrich’s web. In all 13 peer-reviewed articles, the diagnosis of FLD was most commonly done by analyzing ALT and AST liver enzymes and lipid profiles. Liver ultrasound, liver FibroScan, and liver biopsy served as other tools used for detecting the presence of FLD. It was observed that anti-inflammatory, herbal-based, vitamin-based, and plant-based medications and healthy gut microbiota had beneficial and therapeutic effects in treating FLD when coupled with healthy lifestyle changes. All medicinal treatments were found to lower the ALT and AST liver enzymes, lipid profiles (total cholesterol, triglycerides, low-density lipoprotein), and liver steatosis scores in studies where ultrasound was used before and after treatment. Further investigation is needed to fully understand the mechanisms behind the therapeutic effects of treating FLD; however, the medicinal treatments discussed in this review show promising prospects for treating the disease. The therapeutic effects of anti-inflammatory, herbal-based, vitamin-based, and plant-based medications and living a healthy lifestyle were seen in lower levels of liver enzymes, improved lipid profiles, and lower steatosis scores, with no reported side effects on subjects. The treatment options studied may have beneficial impacts in treating FLD patients and may be used in the development of future medications to combat the disease.
format Online
Article
Text
id pubmed-10676744
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-106767442023-10-27 Emerging Diagnostics and Therapeutics for Non-alcoholic Fatty Liver Disease Darbhanga, Jake Krulikowski, Kiarra Riskin, Suzanne I Cureus Family/General Practice The obesity epidemic has pushed fatty liver disease, which consists of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, to the forefront of the 21st century. Disease identification can be done invasively with a liver biopsy or noninvasively through elastography and measurements of biomarkers, such as the alanine aminotransferase (ALT) and aspartate aminotransferase (AST) liver enzymes. Presently, there are no FDA-approved drugs on the market to treat the disease. Alternative medicinal treatments have been investigated, which include altering the intestinal microbiota and consuming anti-inflammatory, herbal-based, vitamin-based, and plant-based medications, in addition to following a healthy lifestyle. In this study, multiple databases were used to identify articles pertaining to fatty liver disease (FLD). Databases included Biomedical Reference Collection: Comprehensive, Cumulative Index of Nursing and Allied Health (CINAHL), Google Scholar, and PubMed. All articles gathered from the databases were peer-reviewed and less than 10 years old to ensure the credibility of the work and recent information regarding the disease. A total of 13 articles were used to gather information for this review. All articles were confirmed to be peer-reviewed by checking them with Ulrich’s web. In all 13 peer-reviewed articles, the diagnosis of FLD was most commonly done by analyzing ALT and AST liver enzymes and lipid profiles. Liver ultrasound, liver FibroScan, and liver biopsy served as other tools used for detecting the presence of FLD. It was observed that anti-inflammatory, herbal-based, vitamin-based, and plant-based medications and healthy gut microbiota had beneficial and therapeutic effects in treating FLD when coupled with healthy lifestyle changes. All medicinal treatments were found to lower the ALT and AST liver enzymes, lipid profiles (total cholesterol, triglycerides, low-density lipoprotein), and liver steatosis scores in studies where ultrasound was used before and after treatment. Further investigation is needed to fully understand the mechanisms behind the therapeutic effects of treating FLD; however, the medicinal treatments discussed in this review show promising prospects for treating the disease. The therapeutic effects of anti-inflammatory, herbal-based, vitamin-based, and plant-based medications and living a healthy lifestyle were seen in lower levels of liver enzymes, improved lipid profiles, and lower steatosis scores, with no reported side effects on subjects. The treatment options studied may have beneficial impacts in treating FLD patients and may be used in the development of future medications to combat the disease. Cureus 2023-10-27 /pmc/articles/PMC10676744/ /pubmed/38021846 http://dx.doi.org/10.7759/cureus.47821 Text en Copyright © 2023, Darbhanga et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Family/General Practice
Darbhanga, Jake
Krulikowski, Kiarra
Riskin, Suzanne I
Emerging Diagnostics and Therapeutics for Non-alcoholic Fatty Liver Disease
title Emerging Diagnostics and Therapeutics for Non-alcoholic Fatty Liver Disease
title_full Emerging Diagnostics and Therapeutics for Non-alcoholic Fatty Liver Disease
title_fullStr Emerging Diagnostics and Therapeutics for Non-alcoholic Fatty Liver Disease
title_full_unstemmed Emerging Diagnostics and Therapeutics for Non-alcoholic Fatty Liver Disease
title_short Emerging Diagnostics and Therapeutics for Non-alcoholic Fatty Liver Disease
title_sort emerging diagnostics and therapeutics for non-alcoholic fatty liver disease
topic Family/General Practice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676744/
https://www.ncbi.nlm.nih.gov/pubmed/38021846
http://dx.doi.org/10.7759/cureus.47821
work_keys_str_mv AT darbhangajake emergingdiagnosticsandtherapeuticsfornonalcoholicfattyliverdisease
AT krulikowskikiarra emergingdiagnosticsandtherapeuticsfornonalcoholicfattyliverdisease
AT riskinsuzannei emergingdiagnosticsandtherapeuticsfornonalcoholicfattyliverdisease